MATERIALS AND METHODS: A retrospective review was conducted on patient data from those who underwent pleuroscopy at Hospital Canselor Tuanku Muhriz from January 2021 to December 2023. We included patients with pleural effusion who underwent both cell block and pleural biopsy with a confirmed diagnosis of malignancy through histopathological examination. At least 200 ml of pleural fluid was collected, followed by the biopsy of six or more pleural tissue samples.
RESULTS: Out of the 196 pleuroscopy procedures analysed, 91 patients were diagnosed with malignant pleural effusion. Malignancy was diagnosed in 50 (54.9%) cases using cell block analysis, whereas pleural biopsy identified malignancy in 81 (89%) cases. The diagnostic yield was significantly higher for pleural biopsy compared to pleural fluid cell block [89% (81/91) vs. 54.9% (50/91); p < 0.001]. Among patients with negative results on pleural fluid cell block, 33 (36.3%) had positive results on pleural biopsy. The definitive diagnoses of malignancy included 64 (70.3%) cases of lung adenocarcinoma, 4 (4.4%) cases of lung squamous carcinoma, 2 (2.2%) cases of small cell lung cancer, 2 (2.2%) cases of mesothelioma, and 19 (20.9%) cases of metastatic carcinoma. Eight (8.8%) patients exhibited negative findings on both pleural fluid cell block and pleural biopsy. Further diagnoses were achieved through computed tomography-guided needle tru-cut biopsy of the lung in 6 patients (6.6%), transbronchial lung biopsy in 1 patient (1.1%), and cervical lymph node biopsy in 1 patient (1.1%).
CONCLUSION: Pleural biopsy exhibits superior diagnostic accuracy compared to pleural fluid cell block analysis for malignant pleural effusion. In cases where cell block results are negative but suspicion remains high, pleural biopsy remains a crucial diagnostic tool.
METHODS: All patients undergoing an initial diagnostic thoracentesis over 18 months with Pf lactate measured using a calibrated point-of-care blood gas analyzer were assessed.
RESULTS: The diagnoses of the enrolled patients (n = 170) included TBE (n = 49), PPE (n = 47), malignancy (n = 63), and transudate (n = 11). Pf lactate level in TBE, median 3.70 (inter-quartile range 2.65-4.90) mmol/l, was significantly lower than in PPE and CPPE. In the subgroup of TBE and CPPE patients whose initial Pf pH and glucose could suggest either condition, Pf lactate was significantly higher in those with CPPE. Pf lactate (cutoff ≥7.25 mmol/l) had a sensitivity of 79.3%, specificity 100%, positive predictive value 100%, and negative predictive value 89.1% for discriminating CPPE from TBE (area under the curve 0.947, p